Glycemic Control and Coagulation Inhibitors in Diabetic Patients
| Autor: | Levent Ündar, Umit Karayalcin, Hasan Altunbaş |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Male
medicine.medical_specialty Antithrombin III Pharmacology Protein S Physiology (medical) Diabetes mellitus Internal medicine Blood plasma medicine Humans Hypoglycemic Agents Blood Coagulation Glycoproteins Glycemic Heparin cofactor II Complement Inactivator Proteins Hematology biology business.industry Middle Aged medicine.disease Receptors Complement Diabetes Mellitus Type 1 Endocrinology Diabetes Mellitus Type 2 Coagulation Heparin Cofactor II biology.protein Female business Protein C medicine.drug |
| Zdroj: | Pathophysiology of Haemostasis and Thrombosis. 28:307-312 |
| ISSN: | 1424-8840 1424-8832 |
| DOI: | 10.1159/000022447 |
| Popis: | Objective: To investigate the plasma antigenic levels and functional activities of coagulation inhibitors in poorly controlled diabetic patients and the possible effect of good glycemic control on these parameters. Research Design and Methods: Both functional activities and plasma antigenic levels of coagulation inhibitors (antithrombin III, heparin cofactor II, protein C, and protein S) and plasma levels of C4b-binding protein were measured in 28 diabetic patients (13 males, 15 females; 2 IDDM, 26 NIDDM; median age 56.5 years; median duration of diabetes 5.5 years) with poor glycemic control (median HbA1c 11.8%). Twenty-three healthy subjects were enrolled as controls. Following a 3-month intensification of antihyperglycemic therapy, good glycemic control (HbA1c Results: Functional activities and plasma antigenic levels of coagulation inhibitors were comparable in poorly controlled diabetic patients and healthy subjects. In patients achieving good control after 3 months, there was a significant reduction in plasma antigenic levels of protein S (p = 0.005) and C4b-binding protein (p = 0.03); however, no difference could be observed in other parameters. HbA1c did not show any correlation with plasma antigenic levels or functional activities of coagulation inhibitors either at baseline or at 3 months of good glycemic control. Conclusions: Our findings suggest that in poorly controlled diabetic patients, coagulation inhibitors are not different from healthy controls. Short-term good glycemic control may not exert a profound effect on coagulation inhibitors except protein S and its binding protein, C4b-binding protein. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|